CDMO Suven’s finished drug exports halted due to Indian COVID-19 lockdown

25 Mar 2020

Indian contract development and manufacturing organisation, Suven Pharmaceuticals, has warned it cannot export finished products due to a shortage of raw materials following the country’s recent lockdown to fight the COVID-19 pandemic.

Suven chairman and managing director Venkat Jasti said in a letter to customers and shareholders dated 25 March that even though Indian pharmaceutical manufacturing is exempted from the lockdown situation, the shortage had arisen because movement of goods both interstate and intrastate has been halted.

CDMO Suven’s finished drug exports halted due to Indian COVID-19 lockdown

“This has…prevented us from being able to export finished products. To compound the situation, the government agencies at the seaports and airports are not operating to inspect and clear those finished goods,” he said.

He added that supply, production and shipment disruptions would all have an “unavoidable” impact on Suven and its customers.

Indian Prime Minister Narendra Modi announced on Tuesday a three-week lockdown for the whole of India. “To save India and every Indian, there will be a total ban on venturing out of your homes,” he said in an address to the nation.

Earlier this month, India restricted exports of 26 APIs including antibiotics, vitamins and hormones. The move by the Directorate General of Foreign Trade was to ensure no shortages of drugs as a result of China’s COVID-19-related lockdown.

And earlier this week, the Indian government approved a USD1.3 billion scheme to boost domestic active pharmaceutical ingredient production and lessen reliance on Chinese imports. The plan involves development of three mega API drug parks in partnership with states and financial incentives to manufacturers of 53 identified critical APIs on incremental sales for the next six years.

In a research note dated 12 March, credit ratings agency India Ratings and Research said Indian pharmaceutical supply chain disruption could be far greater than the China environmental regulation-induced shortfall of 2017 If the COVID-19 outbreak is not contained within the next three months.

Related news

India says shipments of hydroxychloroquine will resume after US exerts pressure

India says shipments of hydroxychloroquine will resume after US exerts pressure

7 Apr 2020

Our content has now moved to our new Global Pharma Insights website, providing the very latest news and information covering all aspects of the pharmaceutical supply chain. Please click the link below to access this article.

Read more 
Chinese CDMOs legislating for the future

Chinese CDMOs legislating for the future

2 Apr 2020

Our content has now moved to our new Global Pharma Insights website, providing the very latest news and information covering all aspects of the pharmaceutical supply chain. Please click the link below to access this article.

Read more 
FDA orders ranitidine withdrawal due to nitrosamine contamination risk

FDA orders ranitidine withdrawal due to nitrosamine contamination risk

2 Apr 2020

Our content has now moved to our new Global Pharma Insights website, providing the very latest news and information covering all aspects of the pharmaceutical supply chain. Please click the link below to access this article.

Read more 
China focused on meeting international API demand amid pandemic, say officials

China focused on meeting international API demand amid pandemic, say officials

1 Apr 2020

Our content has now moved to our new Global Pharma Insights website, providing the very latest news and information covering all aspects of the pharmaceutical supply chain. Please click the link below to access this article.

Read more 
2020 - a year for 'big answers' rather than 'big data'

2020 - a year for 'big answers' rather than 'big data'

7 Feb 2020

Zenith Technologies CEO, Joe Haugh, takes us through how the business has evolved this year, to better meet the needs of its customers, as well as the trends they see shaping the industry through 2020 and beyond.

Read more 
Inovio and Beijing Advaccine to advance vaccine against Coronavirus

Inovio and Beijing Advaccine to advance vaccine against Coronavirus

30 Jan 2020

Agreement will facilitate clinical trial translations in China.

Read more 
AstraZeneca embarks on $1bn zero carbon strategy

AstraZeneca embarks on $1bn zero carbon strategy

24 Jan 2020

The programme will include the launch of next-generation respiratory inhalers, which will use near-zero Global Warming Potential propellants.

Read more 
Diabetes diagnosis - now a matter of sweat and tears?

Diabetes diagnosis - now a matter of sweat and tears?

21 Jan 2020

No need to draw blood; researchers develop smart technology to diagnose diabetes and treat diabetic retinopathy.

Read more 
2019, the year that got serialization done!

2019, the year that got serialization done!

17 Dec 2019

The past 12 months have been busy as many companies fought to comply with serialization regulations.

Read more 
Edible barcodes - it's Tru!

Edible barcodes - it's Tru!

10 Dec 2019

Smart tags on pills set to improve supply chain security and patient adherence.

Read more